Skip to main content
. Author manuscript; available in PMC: 2021 Jul 29.
Published in final edited form as: Med Drug Discov. 2020 Mar 24;6:100023. doi: 10.1016/j.medidd.2020.100023

Fig. 6.

Fig. 6.

Using CaP lipid nanoparticles for the delivery of relaxin-encoding pDNA for tumor immunotherapy. (A) High expression level of sigma-1 receptor (Sig-1R) on activated hepatic stellate cells (aHSCs). (B) Schematic illustration of CaP lipid nanoparticles. A Sig-1R-targeting ligand, aminoethyl anisamide (AEAA), was conjugated on liposome surface for active targeting. (C) Distribution of DiD-labeled CaP lipid nanoparticles and DiD-labeled AEAA-conjugated CaP lipid nanoparticles in the organs after injection in mice bearing liver metastatic CT26-FL3 for 13 days. (D) Relative relaxin mRNA levels after the injection of pDNA CaP lipid nanoparticles. (E) Relative relaxin expression levels after the injection of pDNA CaP lipid nanoparticles. Adapted by permission from reference [61]. Copyright 2019, Springer Nature.